drugset / Trial / NCT04809623
Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this study is to evaluate the safety and tolerability of edecesertib (formerly GS-5718) in participants with cutaneous lupus erythematosus (CLE) with or without systemic lupus erythematosus (SLE).
Timeline
- Start
- 2021-09-01
- Primary completion
- 2022-10-18
- Completion
- 2022-10-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Edecesertib | Small molecule | 115 mg | Oral |
| Background | Azathioprine | Small molecule | — | — |
| Background | Hydroxychloroquine | Small molecule | — | — |
| Background | Methotrexate | Small molecule | — | — |
| Background | Prednisone | Other / unclassified | — | — |